Korean J Hematol 2006; 41(4):
Published online December 30, 2006
https://doi.org/10.5045/kjh.2006.41.4.225
© The Korean Society of Hematology
이재훈, 방수미
가천의과학대학교 길병원 내과, 분당서울대학교병원 내과
Multiple myeloma is a hematologic neoplasm with a unique and characteristic manifestation. This condition is responsible for 10% of hematologic malignancies, and thus represents 1% of all cases of cancer in the US. In Korea, unlike in Western society, myeloma has classically been relatively rare, due in part to racial differences. However, the incidence of this disease in Korea has increased steadily over the last 25 years. During this period, both the incidence of and mortality due to myeloma increased by up to 30-fold. Currently, incidence rate and mortality rate exceed 1.0/100,000. Possible reasons for this increase include better detection, as well as an actual increase, probably attributable to contributing factors, including pollution, exposure to chemicals, and socioeconomic change, all of which are related to rapid industrialization. Aging is another important factor contributing to this perceived increase. With the advent of targeted therapy, Korean myeloma study group was organized under the auspice of Korean society of hematology. In addition, Korean myeloma registry was established recently. In this study, epidemiological changes in the incidence and mortality of multiple myeloma in Korea are assessed and compared with the situations of the US and Japan. This article also claims the need for multicenter clinical trials as well as activation of basic researches in myeloma.
Keywords Epidemiology, Incidence, Mortality, Prevalence, Multiple myeloma
Korean J Hematol 2006; 41(4): 225-234
Published online December 30, 2006 https://doi.org/10.5045/kjh.2006.41.4.225
Copyright © The Korean Society of Hematology.
이재훈, 방수미
가천의과학대학교 길병원 내과, 분당서울대학교병원 내과
Jae Hoon Lee, Soo Mee Bang
Department of Internal Medicine, Gachon University of Medicine and Science Gil Hospital, Incheon,
Seoul National University Bundang Hospital, Bundang, Korea
Multiple myeloma is a hematologic neoplasm with a unique and characteristic manifestation. This condition is responsible for 10% of hematologic malignancies, and thus represents 1% of all cases of cancer in the US. In Korea, unlike in Western society, myeloma has classically been relatively rare, due in part to racial differences. However, the incidence of this disease in Korea has increased steadily over the last 25 years. During this period, both the incidence of and mortality due to myeloma increased by up to 30-fold. Currently, incidence rate and mortality rate exceed 1.0/100,000. Possible reasons for this increase include better detection, as well as an actual increase, probably attributable to contributing factors, including pollution, exposure to chemicals, and socioeconomic change, all of which are related to rapid industrialization. Aging is another important factor contributing to this perceived increase. With the advent of targeted therapy, Korean myeloma study group was organized under the auspice of Korean society of hematology. In addition, Korean myeloma registry was established recently. In this study, epidemiological changes in the incidence and mortality of multiple myeloma in Korea are assessed and compared with the situations of the US and Japan. This article also claims the need for multicenter clinical trials as well as activation of basic researches in myeloma.
Keywords: Epidemiology, Incidence, Mortality, Prevalence, Multiple myeloma
Hyeon Jin Park, Eun-Hye Park, Kyu-Won Jung, Hyun-Joo Kong, Young-Joo Won, Joo Young Lee, Jong Hyung Yoon, Byung-Kiu Park, Hyewon Lee, Hyeon-Seok Eom, and Sohee Park
Korean J Hematol 2012; 47(1): 28-38Yang SH, Kim TY, Kim BK, Koh YW, Kwak DS, Kim NK, Kim SY, Kim SH, Kim SR, Kim JS, Kim JK, Kim JS, Kim HJ, Kim HJ, Park MH, Park S, Park YS, Park JH, Park JW, Park HS, Bang YJ, Seo CI, Seo C, Sohn JW, Song HS, Shim YH, Yoon HJ, Lee KB, Lee SJ, Lee SJ, Lee SN, Yim CY, Jang JS, Jung BC, Jung SI, Jung CH, Cho KJ, Cho KS, Cho HI, Choi IY, Choi JI, Hahn JS, Heo DS
Korean J Hematol 1995; 30(3): 345-361Haerim Chung, Hyunsoo Cho
Blood Res 2023; 58(4): 166-172